Cargando…
Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction
OBJECTIVES: To compare the efficacy and safety of intravenous thrombolysis with alteplase and intravenous thrombolysis with urokinase for patients with acute cerebral infarction. METHODS: This prospective study included 140 patients with acute cerebral infarction who were admitted to our hospital be...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002439/ https://www.ncbi.nlm.nih.gov/pubmed/35480520 http://dx.doi.org/10.12669/pjms.38.3.4521 |
_version_ | 1784685889913356288 |
---|---|
author | Gao, Lilin Zhang, Shaojie Wo, Xuewen Shen, Xiangpeng Tian, Qiangyuan Wang, Guoqing |
author_facet | Gao, Lilin Zhang, Shaojie Wo, Xuewen Shen, Xiangpeng Tian, Qiangyuan Wang, Guoqing |
author_sort | Gao, Lilin |
collection | PubMed |
description | OBJECTIVES: To compare the efficacy and safety of intravenous thrombolysis with alteplase and intravenous thrombolysis with urokinase for patients with acute cerebral infarction. METHODS: This prospective study included 140 patients with acute cerebral infarction who were admitted to our hospital between June 2018 and June 2019. They were randomly divided into two groups. The control group (70 cases) was treated with urokinase intravenous thrombolysis, and the observation group (70 cases) was given alteplase intravenous thrombolytic therapy. The treatment efficacy and safety of the two groups were compared. RESULTS: The total effective rate of the observation group was 95.7%, and that of the control group was 78.6%, i.e., the total effective rate of the observation group was significantly superior to the that of the control group (P < 0.05). After treatment, the observation group had significantly lower National Institutes of Health Stroke Scale (NIHSS) score and significantly higher mini-mental state examination (MMSE) score than the control group; the difference was statistically significant (P<0.05). After treatment, the levels of inflammatory factors of both groups significantly decreased compared to before treatment, and the decrease in the observation group was larger than that in the control group (P<0.05). The levels of serum homocysteine (Hcy) and monocyte chemoattractant protein-1 (MCP-1) in the observation group were significantly lower than those in the control group after treatment, and the differences were statistically significant (P<0.05). The incidence of hemorrhagic adverse reaction in the observation group was lower than that in the control group (P<0.05). CONCLUSION: In the treatment of acute cerebral infarction, ccompared with urokinase, alteplase can further relieve cognitive impairment and promote the recovery of nerve function through inhibiting levels of inflammatory factors and levels of serum Hcy and MCP-1. |
format | Online Article Text |
id | pubmed-9002439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Professional Medical Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-90024392022-04-26 Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction Gao, Lilin Zhang, Shaojie Wo, Xuewen Shen, Xiangpeng Tian, Qiangyuan Wang, Guoqing Pak J Med Sci Original Article OBJECTIVES: To compare the efficacy and safety of intravenous thrombolysis with alteplase and intravenous thrombolysis with urokinase for patients with acute cerebral infarction. METHODS: This prospective study included 140 patients with acute cerebral infarction who were admitted to our hospital between June 2018 and June 2019. They were randomly divided into two groups. The control group (70 cases) was treated with urokinase intravenous thrombolysis, and the observation group (70 cases) was given alteplase intravenous thrombolytic therapy. The treatment efficacy and safety of the two groups were compared. RESULTS: The total effective rate of the observation group was 95.7%, and that of the control group was 78.6%, i.e., the total effective rate of the observation group was significantly superior to the that of the control group (P < 0.05). After treatment, the observation group had significantly lower National Institutes of Health Stroke Scale (NIHSS) score and significantly higher mini-mental state examination (MMSE) score than the control group; the difference was statistically significant (P<0.05). After treatment, the levels of inflammatory factors of both groups significantly decreased compared to before treatment, and the decrease in the observation group was larger than that in the control group (P<0.05). The levels of serum homocysteine (Hcy) and monocyte chemoattractant protein-1 (MCP-1) in the observation group were significantly lower than those in the control group after treatment, and the differences were statistically significant (P<0.05). The incidence of hemorrhagic adverse reaction in the observation group was lower than that in the control group (P<0.05). CONCLUSION: In the treatment of acute cerebral infarction, ccompared with urokinase, alteplase can further relieve cognitive impairment and promote the recovery of nerve function through inhibiting levels of inflammatory factors and levels of serum Hcy and MCP-1. Professional Medical Publications 2022 /pmc/articles/PMC9002439/ /pubmed/35480520 http://dx.doi.org/10.12669/pjms.38.3.4521 Text en Copyright: © Pakistan Journal of Medical Sciences https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0 (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Gao, Lilin Zhang, Shaojie Wo, Xuewen Shen, Xiangpeng Tian, Qiangyuan Wang, Guoqing Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction |
title | Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction |
title_full | Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction |
title_fullStr | Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction |
title_full_unstemmed | Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction |
title_short | Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction |
title_sort | intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002439/ https://www.ncbi.nlm.nih.gov/pubmed/35480520 http://dx.doi.org/10.12669/pjms.38.3.4521 |
work_keys_str_mv | AT gaolilin intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction AT zhangshaojie intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction AT woxuewen intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction AT shenxiangpeng intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction AT tianqiangyuan intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction AT wangguoqing intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction |